Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of argatroban (a direct thrombin inhibitor), aspirin (an antiplatelet agent), intravenous immunoglobulin (gammaglobulin), and prednisolone (a corticosteroid). While argatroban and aspirin combinations have been studied for prevention of coronary thrombosis and treatment of acute ischemic stroke, the specific four-drug combination including gammaglobulin and prednisolone is not well-documented in the literature. Argatroban is a synthetic direct thrombin inhibitor used for prevention and treatment of thrombosis, particularly in patients with heparin-induced thrombocytopenia (HIT). Aspirin functions as an antiplatelet agent through inhibition of thromboxane synthesis. The combination of argatroban and aspirin has shown potential efficacy in preventing coronary thrombosis and treating certain types of stroke.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on argatroban + aspirin + gammaglobulin + prednisolone.